OVID
Ovid Therapeutics Inc
2.50$
+3.3%
vs. previous close
Closing price · As of: Sep 29, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +1,348.6% | -24.7% | +68.7% | -46.7% | +69.7% | -6.1% | +156.2% | -20.2% | -7.2% | -36.0% | +63.8% | |
| – | +1,349.8% | -25.4% | +69.0% | -50.0% | +80.3% | -6.2% | +154.5% | -31.0% | -16.6% | -49.0% | +61.7% | |
| – | +1,343.1% | -25.7% | +67.7% | -58.1% | +14.8% | +71.9% | +160.7% | -76.1% | -39.7% | -2.7% | -50.0% | |
| – | +1,343.1% | -25.7% | +67.7% | -52.4% | +84.9% | -6.1% | +160.7% | -31.3% | -18.0% | -49.9% | +31.2% | |
| – | – | -87.4% | – | – | +88.5% | -87.5% | – | – | – | – | – | |
| – | – | – | -100.0% | – | – | – | – | – | – | – | – | |
| – | +2,107.6% | +47.7% | +18.8% | +34.9% | -2.2% | +98.4% | +79.0% | +372.9% | – | – | – | |
| – | – | – | – | – | – | – | -96,134.0% | – | – | – | – | |
| – | +651.4% | +482.7% | +12.8% | +215.5% | +19.2% | -31.7% | -48.6% | +35.4% | -10.0% | -54.0% | – | |
| – | +1,825.1% | +61.7% | +61.3% | +46.9% | +22.3% | +198.5% | -54.2% | +55.4% | +144.6% | -57.4% | -15.3% | |
| – | +1,825.1% | +61.7% | +61.3% | +46.9% | +19.1% | +109.5% | -32.9% | -52.8% | +64.1% | -8.3% | -21.2% | |
| – | – | – | – | – | – | – | – | – | +133.4% | +7.2% | +7.3% | |
| – | +747.3% | +27.8% | +136.3% | +85.4% | -13.3% | +67.3% | +30.9% | -72.6% | +89.6% | -13.8% | -38.7% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +1,336.6% | -27.6% | +69.3% | -53.5% | +80.4% | -37.7% | +312.0% | -26.4% | -33.6% | -22.3% | +91.5% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +312.4% | +0.0% | -1.3% | +27.3% | +59.2% | +49.0% | +16.5% | +3.5% | +0.2% | +0.5% | +4.0% |
Data as of: September 29, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.